• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

    2/14/24 9:00:06 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    SC 13G/A 1 fp0086874-2_sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 2)*

     

    BIOMERICA, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.08

    (Title of Class of Securities)

     

    09061H307

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x]Rule 13d-1(b)
    [  ]Rule 13d-1(c)
    [  ]Rule 13d-1(d)

     

    ____________________

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP NO. 09061H307

    13G Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS S.S. OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    Granahan Investment Management LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a) [ ]

    (b) [ ]

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Massachusetts

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    929,042

     
    6

    SHARED VOTING POWER

     

    None

     
    7

    SOLE DISPOSITIVE POWER

     

    1,082,672

     
    8

    SHARED DISPOSITIVE POWER

     

    None

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,082,672

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

     

    [ ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    6.44%

     
    12

    TYPE OF REPORTING PERSON

     

    IA

     
             

     

     

    CUSIP NO. 09061H307 13G Page 3 of 5 Pages

     

    Item 1.(a) Name of Issuer:

     

    BIOMERICA, INC

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    17571 Von Karman Avenue

    Irvine, CA 92614

     

    Item 2.(a) Name of Person Filing:

     

    Granahan Investment Management LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    Wyman Street, Suite 460

    Waltham, MA 02451

     

    (c)Citizenship:

     

    State of Massachusetts

     

    (d)Title of Class of Securities:

     

    Common Stock, par value $0.08

     

    (e)CUSIP Number:

     

    09061H307

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)[ ] Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b)[ ] Bank as defined in Section 3(a)(6) of the Exchange Act.

     

    (c)[ ] Insurance company as defined in Section 3(a)(19) of the Exchange Act.

     

    (d)[ ] Investment company registered under Section 8 of the Investment Company Act.

     

    (e[X] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)[ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)[ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    (j)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

     

     

    CUSIP NO. 09061H307 13G Page 4 of 5 Pages

     

    Item 4.Ownership.

     

         
    (a) Amount beneficially owned: 1,082,672
    (b) Percent of class: 6.44%
    (c) Number of shares as to which the person has:  
      (i) Sole power to vote or to direct the vote: 929,042
      (ii) Shared power to vote or to direct the vote: 0
      (iii) Sole power to dispose or to direct the disposition of: 1,082,672
      (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [ ]

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the Shares set forth in Item 4 are owned by various investment advisory clients of Granahan Investment Management LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares and/or its ability to vote such shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable

     

     

     

    CUSIP NO. 09061H307 13G Page 5 of 5 Pages

     

    Item 10.Certification.

     

    By signing below the undersigned certifies that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Granahan Investment Management LLC  
           
      By: /s/ Brian Granahan  
      Name: Brian Granahan  
      Title: Chief Compliance Officer  
           
      Date: February 14, 2024  

    Get the next $BMRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:09 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Moatazedi David was granted 85,000 shares (SEC Form 4)

      4 - BIOMERICA INC (0000073290) (Issuer)

      12/17/24 7:30:07 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

      IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, "LabCorp" (NYSE:LH), brings extensive expertise to collaborate with Jack Kenny, Chairman of Biomerica, and Zack Irani, CEO of Biomerica, in driving expansion of the inFoods® IBS product. Most recently, Mr. Huff served as the CEO of LabCorp Diagnostics, overseeing one of the world's largest diagnostics clinical laboratories, boasting $7B in annual revenues, ov

      2/21/24 8:19:00 AM ET
      $BMRA
      $LH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Medical Specialities
    • Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

      Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to serve as the Chairman of the Board of Directors of Biomerica. Mr. Zack Irani will continue to serve as CEO. Mr. Kenny joined the Biomerica Board of Director

      1/23/24 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Diagnostics Industry Leader Jack Kenny Joins Biomerica's Board of Directors

      Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board member of Meridian Bioscience, Inc., to its Board of Directors. Meridian Biosciences (formerly traded on Nasdaq under VIVO) is a leadin

      8/28/23 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BMRA
    SEC Filings

    See more
    • Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods® IBS using a First of Its Kind Real-Time IBS Patient Feedback System

      Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind inFoods® IBS Feedback Platform: New real-time feedback system empowers physicians to adjust patient treatment based on actionable, patient-reported outcomesPrecision Medicine: inFoods® IBS identifies specific individual food triggers that can cause IBS symptoms (bloating, pain, diarrhea, and constipation) offering a personalized, non-drug solution IRVINE, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), an innovator in diagnostic-guided therapy, today anno

      5/22/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PLA Code Application Filed for inFoods IBS Test — A Key Step Toward Reimbursement

      - Application represents milestone toward broadening patient access to inFoods IBS - inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and constipation IRVINE, Calif. , May 07, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company dedicated to the development of advanced diagnostic products, announced that the Company and its CLIA laboratory partner have submitted an application to the American Medical Association (AMA) CPT Editorial Panel requesting the assignment of a Proprietary Laboratory Analysis (PLA) code for the inFoods® IBS diagnostic test. If granted, the PLA

      5/7/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Ulcer Test for Detection of H. pylori Infection

      10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogenThis test empowers healthcare providers with fast, accessible testing across the UAE IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Heli

      4/23/25 8:19:00 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biomerica Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BIOMERICA INC (0000073290) (Filer)

      4/16/25 9:00:09 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      4/14/25 4:15:33 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Biomerica Inc.

      10-Q - BIOMERICA INC (0000073290) (Filer)

      1/14/25 5:06:05 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Financials

    Live finance-specific insights

    See more
    • Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

      InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

      1/13/23 6:39:00 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      11/14/24 4:19:51 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

      SC 13G/A - BIOMERICA INC (0000073290) (Subject)

      2/14/24 9:00:06 AM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Biomerica Inc.

      SC 13G - BIOMERICA INC (0000073290) (Subject)

      2/9/24 3:06:57 PM ET
      $BMRA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care